nodes	percent_of_prediction	percent_of_DWPC	metapath
Mitoxantrone—Topoisomerase Inhibitors—Teniposide—lymphatic system cancer	0.74	1	CiPCiCtD
Mitoxantrone—TOP2A—Teniposide—lymphatic system cancer	0.0812	0.419	CbGbCtD
Mitoxantrone—ABCG2—Teniposide—lymphatic system cancer	0.0301	0.155	CbGbCtD
Mitoxantrone—ABCC1—Vincristine—lymphatic system cancer	0.0217	0.112	CbGbCtD
Mitoxantrone—ABCG2—Vincristine—lymphatic system cancer	0.0145	0.0747	CbGbCtD
Mitoxantrone—ABCC1—Methotrexate—lymphatic system cancer	0.0131	0.0676	CbGbCtD
Mitoxantrone—ABCG2—Methotrexate—lymphatic system cancer	0.00878	0.0452	CbGbCtD
Mitoxantrone—CYP3A4—Cytarabine—lymphatic system cancer	0.00661	0.034	CbGbCtD
Mitoxantrone—CYP3A4—Teniposide—lymphatic system cancer	0.00651	0.0335	CbGbCtD
Mitoxantrone—ABCB1—Vincristine—lymphatic system cancer	0.00523	0.0269	CbGbCtD
Mitoxantrone—ABCB1—Methotrexate—lymphatic system cancer	0.00317	0.0163	CbGbCtD
Mitoxantrone—CYP3A4—Vincristine—lymphatic system cancer	0.00313	0.0161	CbGbCtD
Mitoxantrone—TOP2A—Etoposide—Teniposide—lymphatic system cancer	0.000333	0.195	CbGdCrCtD
Mitoxantrone—TOP2A—Podofilox—Teniposide—lymphatic system cancer	0.000254	0.149	CbGdCrCtD
Mitoxantrone—TOP2A—Vindesine—Vincristine—lymphatic system cancer	0.000239	0.14	CbGdCrCtD
Mitoxantrone—TOP2A—Vinorelbine—Vincristine—lymphatic system cancer	0.000151	0.0884	CbGdCrCtD
Mitoxantrone—Leukopenia—Fludarabine—lymphatic system cancer	0.000138	0.00216	CcSEcCtD
Mitoxantrone—Haematuria—Bleomycin—lymphatic system cancer	0.000138	0.00216	CcSEcCtD
Mitoxantrone—Anorexia—Teniposide—lymphatic system cancer	0.000136	0.00213	CcSEcCtD
Mitoxantrone—Fungal infection—Methotrexate—lymphatic system cancer	0.000135	0.00212	CcSEcCtD
Mitoxantrone—Cough—Fludarabine—lymphatic system cancer	0.000135	0.0021	CcSEcCtD
Mitoxantrone—Pancytopenia—Carmustine—lymphatic system cancer	0.000134	0.0021	CcSEcCtD
Mitoxantrone—Hypotension—Teniposide—lymphatic system cancer	0.000134	0.00209	CcSEcCtD
Mitoxantrone—Convulsion—Fludarabine—lymphatic system cancer	0.000134	0.00209	CcSEcCtD
Mitoxantrone—Necrosis—Methotrexate—lymphatic system cancer	0.000133	0.00208	CcSEcCtD
Mitoxantrone—Diarrhoea—Mechlorethamine—lymphatic system cancer	0.000133	0.00208	CcSEcCtD
Mitoxantrone—Neutropenia—Carmustine—lymphatic system cancer	0.000132	0.00207	CcSEcCtD
Mitoxantrone—Myalgia—Fludarabine—lymphatic system cancer	0.000131	0.00205	CcSEcCtD
Mitoxantrone—Arthralgia—Fludarabine—lymphatic system cancer	0.000131	0.00205	CcSEcCtD
Mitoxantrone—Haemoglobin—Bleomycin—lymphatic system cancer	0.000131	0.00204	CcSEcCtD
Mitoxantrone—Haemorrhage—Bleomycin—lymphatic system cancer	0.00013	0.00203	CcSEcCtD
Mitoxantrone—Discomfort—Fludarabine—lymphatic system cancer	0.00013	0.00203	CcSEcCtD
Mitoxantrone—Pancytopenia—Vincristine—lymphatic system cancer	0.000128	0.00201	CcSEcCtD
Mitoxantrone—Hyperglycaemia—Carmustine—lymphatic system cancer	0.000128	0.002	CcSEcCtD
Mitoxantrone—Dyspnoea—Teniposide—lymphatic system cancer	0.000128	0.00199	CcSEcCtD
Mitoxantrone—Petechiae—Methotrexate—lymphatic system cancer	0.000127	0.00199	CcSEcCtD
Mitoxantrone—Pneumonia—Carmustine—lymphatic system cancer	0.000127	0.00198	CcSEcCtD
Mitoxantrone—Confusional state—Fludarabine—lymphatic system cancer	0.000127	0.00198	CcSEcCtD
Mitoxantrone—Neutropenia—Vincristine—lymphatic system cancer	0.000126	0.00198	CcSEcCtD
Mitoxantrone—Oedema—Fludarabine—lymphatic system cancer	0.000126	0.00197	CcSEcCtD
Mitoxantrone—Anaphylactic shock—Fludarabine—lymphatic system cancer	0.000126	0.00197	CcSEcCtD
Mitoxantrone—Infection—Fludarabine—lymphatic system cancer	0.000125	0.00195	CcSEcCtD
Mitoxantrone—Erectile dysfunction—Vincristine—lymphatic system cancer	0.000125	0.00195	CcSEcCtD
Mitoxantrone—Decreased appetite—Teniposide—lymphatic system cancer	0.000124	0.00195	CcSEcCtD
Mitoxantrone—Renal failure—Carmustine—lymphatic system cancer	0.000124	0.00194	CcSEcCtD
Mitoxantrone—Vomiting—Mechlorethamine—lymphatic system cancer	0.000123	0.00193	CcSEcCtD
Mitoxantrone—Thrombocytopenia—Fludarabine—lymphatic system cancer	0.000123	0.00193	CcSEcCtD
Mitoxantrone—Stomatitis—Carmustine—lymphatic system cancer	0.000123	0.00192	CcSEcCtD
Mitoxantrone—Urinary tract infection—Carmustine—lymphatic system cancer	0.000123	0.00192	CcSEcCtD
Mitoxantrone—Rash—Mechlorethamine—lymphatic system cancer	0.000122	0.00191	CcSEcCtD
Mitoxantrone—Dermatitis—Mechlorethamine—lymphatic system cancer	0.000122	0.00191	CcSEcCtD
Mitoxantrone—Weight decreased—Vincristine—lymphatic system cancer	0.000122	0.00191	CcSEcCtD
Mitoxantrone—Hyperhidrosis—Fludarabine—lymphatic system cancer	0.000122	0.0019	CcSEcCtD
Mitoxantrone—Pneumonia—Vincristine—lymphatic system cancer	0.000121	0.00189	CcSEcCtD
Mitoxantrone—Anorexia—Fludarabine—lymphatic system cancer	0.00012	0.00187	CcSEcCtD
Mitoxantrone—Extravasation—Methotrexate—lymphatic system cancer	0.00012	0.00187	CcSEcCtD
Mitoxantrone—Proteinuria—Methotrexate—lymphatic system cancer	0.000119	0.00186	CcSEcCtD
Mitoxantrone—Acute coronary syndrome—Vincristine—lymphatic system cancer	0.000119	0.00186	CcSEcCtD
Mitoxantrone—Myocardial infarction—Vincristine—lymphatic system cancer	0.000118	0.00185	CcSEcCtD
Mitoxantrone—Feeling abnormal—Teniposide—lymphatic system cancer	0.000118	0.00184	CcSEcCtD
Mitoxantrone—Stomatitis—Vincristine—lymphatic system cancer	0.000118	0.00184	CcSEcCtD
Mitoxantrone—Protein urine present—Methotrexate—lymphatic system cancer	0.000117	0.00183	CcSEcCtD
Mitoxantrone—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.000117	0.00183	CcSEcCtD
Mitoxantrone—Chills—Bleomycin—lymphatic system cancer	0.000117	0.00182	CcSEcCtD
Mitoxantrone—Sweating—Vincristine—lymphatic system cancer	0.000116	0.00181	CcSEcCtD
Mitoxantrone—Nausea—Mechlorethamine—lymphatic system cancer	0.000115	0.0018	CcSEcCtD
Mitoxantrone—Alopecia—Bleomycin—lymphatic system cancer	0.000115	0.00179	CcSEcCtD
Mitoxantrone—Musculoskeletal discomfort—Fludarabine—lymphatic system cancer	0.000115	0.00179	CcSEcCtD
Mitoxantrone—TOP2A—Cladribine—Fludarabine—lymphatic system cancer	0.000114	0.0669	CbGdCrCtD
Mitoxantrone—Haemoglobin—Carmustine—lymphatic system cancer	0.000114	0.00178	CcSEcCtD
Mitoxantrone—Urticaria—Teniposide—lymphatic system cancer	0.000114	0.00178	CcSEcCtD
Mitoxantrone—Haemorrhage—Carmustine—lymphatic system cancer	0.000113	0.00177	CcSEcCtD
Mitoxantrone—Body temperature increased—Teniposide—lymphatic system cancer	0.000113	0.00177	CcSEcCtD
Mitoxantrone—Abdominal pain—Teniposide—lymphatic system cancer	0.000113	0.00177	CcSEcCtD
Mitoxantrone—Erythema—Bleomycin—lymphatic system cancer	0.000113	0.00177	CcSEcCtD
Mitoxantrone—Paraesthesia—Fludarabine—lymphatic system cancer	0.000113	0.00177	CcSEcCtD
Mitoxantrone—Hyperuricaemia—Methotrexate—lymphatic system cancer	0.000113	0.00176	CcSEcCtD
Mitoxantrone—Dyspnoea—Fludarabine—lymphatic system cancer	0.000112	0.00175	CcSEcCtD
Mitoxantrone—Dyspepsia—Fludarabine—lymphatic system cancer	0.000111	0.00173	CcSEcCtD
Mitoxantrone—Ulcer—Methotrexate—lymphatic system cancer	0.000111	0.00173	CcSEcCtD
Mitoxantrone—Hepatic enzyme increased—Methotrexate—lymphatic system cancer	0.000111	0.00173	CcSEcCtD
Mitoxantrone—Decreased appetite—Fludarabine—lymphatic system cancer	0.000109	0.00171	CcSEcCtD
Mitoxantrone—Fatigue—Fludarabine—lymphatic system cancer	0.000108	0.0017	CcSEcCtD
Mitoxantrone—Constipation—Fludarabine—lymphatic system cancer	0.000108	0.00168	CcSEcCtD
Mitoxantrone—Pain—Fludarabine—lymphatic system cancer	0.000108	0.00168	CcSEcCtD
Mitoxantrone—Blood uric acid increased—Methotrexate—lymphatic system cancer	0.000106	0.00166	CcSEcCtD
Mitoxantrone—TOP2A—Clofarabine—Fludarabine—lymphatic system cancer	0.000106	0.0619	CbGdCrCtD
Mitoxantrone—Hypersensitivity—Teniposide—lymphatic system cancer	0.000105	0.00165	CcSEcCtD
Mitoxantrone—Ill-defined disorder—Bleomycin—lymphatic system cancer	0.000105	0.00164	CcSEcCtD
Mitoxantrone—Anaemia—Bleomycin—lymphatic system cancer	0.000104	0.00163	CcSEcCtD
Mitoxantrone—TOP2A—Vinblastine—Vincristine—lymphatic system cancer	0.000104	0.0608	CbGdCrCtD
Mitoxantrone—Feeling abnormal—Fludarabine—lymphatic system cancer	0.000104	0.00162	CcSEcCtD
Mitoxantrone—Asthenia—Teniposide—lymphatic system cancer	0.000103	0.00161	CcSEcCtD
Mitoxantrone—Malaise—Bleomycin—lymphatic system cancer	0.000102	0.00159	CcSEcCtD
Mitoxantrone—Arrhythmia—Carmustine—lymphatic system cancer	0.000101	0.00158	CcSEcCtD
Mitoxantrone—Leukopenia—Bleomycin—lymphatic system cancer	0.000101	0.00158	CcSEcCtD
Mitoxantrone—Alopecia—Carmustine—lymphatic system cancer	0.0001	0.00157	CcSEcCtD
Mitoxantrone—TOP2A—Clofarabine—Cytarabine—lymphatic system cancer	9.97e-05	0.0584	CbGdCrCtD
Mitoxantrone—Body temperature increased—Fludarabine—lymphatic system cancer	9.95e-05	0.00155	CcSEcCtD
Mitoxantrone—Erythema—Carmustine—lymphatic system cancer	9.87e-05	0.00154	CcSEcCtD
Mitoxantrone—Cough—Bleomycin—lymphatic system cancer	9.87e-05	0.00154	CcSEcCtD
Mitoxantrone—Diarrhoea—Teniposide—lymphatic system cancer	9.8e-05	0.00153	CcSEcCtD
Mitoxantrone—Chest pain—Bleomycin—lymphatic system cancer	9.62e-05	0.0015	CcSEcCtD
Mitoxantrone—Myalgia—Bleomycin—lymphatic system cancer	9.62e-05	0.0015	CcSEcCtD
Mitoxantrone—Alopecia—Vincristine—lymphatic system cancer	9.56e-05	0.00149	CcSEcCtD
Mitoxantrone—Back pain—Carmustine—lymphatic system cancer	9.55e-05	0.00149	CcSEcCtD
Mitoxantrone—Discomfort—Bleomycin—lymphatic system cancer	9.51e-05	0.00149	CcSEcCtD
Mitoxantrone—Ecchymosis—Methotrexate—lymphatic system cancer	9.45e-05	0.00148	CcSEcCtD
Mitoxantrone—Confusional state—Bleomycin—lymphatic system cancer	9.3e-05	0.00145	CcSEcCtD
Mitoxantrone—Vision blurred—Carmustine—lymphatic system cancer	9.3e-05	0.00145	CcSEcCtD
Mitoxantrone—Hypersensitivity—Fludarabine—lymphatic system cancer	9.27e-05	0.00145	CcSEcCtD
Mitoxantrone—TOP2A—Gemcitabine—Cytarabine—lymphatic system cancer	9.24e-05	0.0541	CbGdCrCtD
Mitoxantrone—Anaphylactic shock—Bleomycin—lymphatic system cancer	9.23e-05	0.00144	CcSEcCtD
Mitoxantrone—Oedema—Bleomycin—lymphatic system cancer	9.23e-05	0.00144	CcSEcCtD
Mitoxantrone—Infection—Bleomycin—lymphatic system cancer	9.17e-05	0.00143	CcSEcCtD
Mitoxantrone—Anaemia—Carmustine—lymphatic system cancer	9.12e-05	0.00143	CcSEcCtD
Mitoxantrone—Back pain—Vincristine—lymphatic system cancer	9.11e-05	0.00142	CcSEcCtD
Mitoxantrone—Vomiting—Teniposide—lymphatic system cancer	9.1e-05	0.00142	CcSEcCtD
Mitoxantrone—Sepsis—Methotrexate—lymphatic system cancer	9.07e-05	0.00142	CcSEcCtD
Mitoxantrone—Thrombocytopenia—Bleomycin—lymphatic system cancer	9.03e-05	0.00141	CcSEcCtD
Mitoxantrone—Asthenia—Fludarabine—lymphatic system cancer	9.03e-05	0.00141	CcSEcCtD
Mitoxantrone—Rash—Teniposide—lymphatic system cancer	9.03e-05	0.00141	CcSEcCtD
Mitoxantrone—Dermatitis—Teniposide—lymphatic system cancer	9.02e-05	0.00141	CcSEcCtD
Mitoxantrone—TOP2A—Cytarabine—Fludarabine—lymphatic system cancer	8.99e-05	0.0526	CbGdCrCtD
Mitoxantrone—Headache—Teniposide—lymphatic system cancer	8.97e-05	0.0014	CcSEcCtD
Mitoxantrone—Leukopenia—Carmustine—lymphatic system cancer	8.83e-05	0.00138	CcSEcCtD
Mitoxantrone—Anorexia—Bleomycin—lymphatic system cancer	8.79e-05	0.00137	CcSEcCtD
Mitoxantrone—Anaemia—Vincristine—lymphatic system cancer	8.71e-05	0.00136	CcSEcCtD
Mitoxantrone—Hypotension—Bleomycin—lymphatic system cancer	8.62e-05	0.00135	CcSEcCtD
Mitoxantrone—Diarrhoea—Fludarabine—lymphatic system cancer	8.61e-05	0.00135	CcSEcCtD
Mitoxantrone—Convulsion—Carmustine—lymphatic system cancer	8.55e-05	0.00134	CcSEcCtD
Mitoxantrone—Hypertension—Carmustine—lymphatic system cancer	8.52e-05	0.00133	CcSEcCtD
Mitoxantrone—Nausea—Teniposide—lymphatic system cancer	8.5e-05	0.00133	CcSEcCtD
Mitoxantrone—Leukopenia—Vincristine—lymphatic system cancer	8.43e-05	0.00132	CcSEcCtD
Mitoxantrone—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	8.41e-05	0.00131	CcSEcCtD
Mitoxantrone—Chest pain—Carmustine—lymphatic system cancer	8.4e-05	0.00131	CcSEcCtD
Mitoxantrone—Myalgia—Carmustine—lymphatic system cancer	8.4e-05	0.00131	CcSEcCtD
Mitoxantrone—Anxiety—Carmustine—lymphatic system cancer	8.37e-05	0.00131	CcSEcCtD
Mitoxantrone—Paraesthesia—Bleomycin—lymphatic system cancer	8.28e-05	0.00129	CcSEcCtD
Mitoxantrone—Dyspnoea—Bleomycin—lymphatic system cancer	8.23e-05	0.00129	CcSEcCtD
Mitoxantrone—Renal failure acute—Methotrexate—lymphatic system cancer	8.22e-05	0.00128	CcSEcCtD
Mitoxantrone—Convulsion—Vincristine—lymphatic system cancer	8.16e-05	0.00128	CcSEcCtD
Mitoxantrone—Hypertension—Vincristine—lymphatic system cancer	8.13e-05	0.00127	CcSEcCtD
Mitoxantrone—Confusional state—Carmustine—lymphatic system cancer	8.12e-05	0.00127	CcSEcCtD
Mitoxantrone—Oedema—Carmustine—lymphatic system cancer	8.05e-05	0.00126	CcSEcCtD
Mitoxantrone—Decreased appetite—Bleomycin—lymphatic system cancer	8.02e-05	0.00125	CcSEcCtD
Mitoxantrone—Myalgia—Vincristine—lymphatic system cancer	8.02e-05	0.00125	CcSEcCtD
Mitoxantrone—Infection—Carmustine—lymphatic system cancer	8e-05	0.00125	CcSEcCtD
Mitoxantrone—Vomiting—Fludarabine—lymphatic system cancer	8e-05	0.00125	CcSEcCtD
Mitoxantrone—Rash—Fludarabine—lymphatic system cancer	7.93e-05	0.00124	CcSEcCtD
Mitoxantrone—Dermatitis—Fludarabine—lymphatic system cancer	7.93e-05	0.00124	CcSEcCtD
Mitoxantrone—Pain—Bleomycin—lymphatic system cancer	7.89e-05	0.00123	CcSEcCtD
Mitoxantrone—Thrombocytopenia—Carmustine—lymphatic system cancer	7.89e-05	0.00123	CcSEcCtD
Mitoxantrone—Headache—Fludarabine—lymphatic system cancer	7.88e-05	0.00123	CcSEcCtD
Mitoxantrone—Tachycardia—Carmustine—lymphatic system cancer	7.86e-05	0.00123	CcSEcCtD
Mitoxantrone—Anaphylactoid reaction—Methotrexate—lymphatic system cancer	7.84e-05	0.00123	CcSEcCtD
Mitoxantrone—Anaphylactic shock—Vincristine—lymphatic system cancer	7.69e-05	0.0012	CcSEcCtD
Mitoxantrone—Oedema—Vincristine—lymphatic system cancer	7.69e-05	0.0012	CcSEcCtD
Mitoxantrone—Anorexia—Carmustine—lymphatic system cancer	7.68e-05	0.0012	CcSEcCtD
Mitoxantrone—Infection—Vincristine—lymphatic system cancer	7.64e-05	0.00119	CcSEcCtD
Mitoxantrone—Feeling abnormal—Bleomycin—lymphatic system cancer	7.6e-05	0.00119	CcSEcCtD
Mitoxantrone—Thrombocytopenia—Vincristine—lymphatic system cancer	7.53e-05	0.00118	CcSEcCtD
Mitoxantrone—Hypotension—Carmustine—lymphatic system cancer	7.53e-05	0.00118	CcSEcCtD
Mitoxantrone—Nausea—Fludarabine—lymphatic system cancer	7.47e-05	0.00117	CcSEcCtD
Mitoxantrone—Hyperhidrosis—Vincristine—lymphatic system cancer	7.43e-05	0.00116	CcSEcCtD
Mitoxantrone—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	7.34e-05	0.00115	CcSEcCtD
Mitoxantrone—Urticaria—Bleomycin—lymphatic system cancer	7.33e-05	0.00115	CcSEcCtD
Mitoxantrone—Anorexia—Vincristine—lymphatic system cancer	7.33e-05	0.00115	CcSEcCtD
Mitoxantrone—Body temperature increased—Bleomycin—lymphatic system cancer	7.29e-05	0.00114	CcSEcCtD
Mitoxantrone—Paraesthesia—Carmustine—lymphatic system cancer	7.23e-05	0.00113	CcSEcCtD
Mitoxantrone—Hypotension—Vincristine—lymphatic system cancer	7.18e-05	0.00112	CcSEcCtD
Mitoxantrone—Dyspnoea—Carmustine—lymphatic system cancer	7.18e-05	0.00112	CcSEcCtD
Mitoxantrone—Somnolence—Carmustine—lymphatic system cancer	7.16e-05	0.00112	CcSEcCtD
Mitoxantrone—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	7e-05	0.00109	CcSEcCtD
Mitoxantrone—Decreased appetite—Carmustine—lymphatic system cancer	7e-05	0.00109	CcSEcCtD
Mitoxantrone—Paraesthesia—Vincristine—lymphatic system cancer	6.9e-05	0.00108	CcSEcCtD
Mitoxantrone—Pain—Carmustine—lymphatic system cancer	6.89e-05	0.00108	CcSEcCtD
Mitoxantrone—Constipation—Carmustine—lymphatic system cancer	6.89e-05	0.00108	CcSEcCtD
Mitoxantrone—Hypersensitivity—Bleomycin—lymphatic system cancer	6.8e-05	0.00106	CcSEcCtD
Mitoxantrone—Decreased appetite—Vincristine—lymphatic system cancer	6.68e-05	0.00104	CcSEcCtD
Mitoxantrone—Feeling abnormal—Carmustine—lymphatic system cancer	6.64e-05	0.00104	CcSEcCtD
Mitoxantrone—Fatigue—Vincristine—lymphatic system cancer	6.63e-05	0.00104	CcSEcCtD
Mitoxantrone—Asthenia—Bleomycin—lymphatic system cancer	6.62e-05	0.00103	CcSEcCtD
Mitoxantrone—Gastrointestinal pain—Carmustine—lymphatic system cancer	6.59e-05	0.00103	CcSEcCtD
Mitoxantrone—Constipation—Vincristine—lymphatic system cancer	6.57e-05	0.00103	CcSEcCtD
Mitoxantrone—Pain—Vincristine—lymphatic system cancer	6.57e-05	0.00103	CcSEcCtD
Mitoxantrone—TOP2A—Azacitidine—Fludarabine—lymphatic system cancer	6.44e-05	0.0377	CbGdCrCtD
Mitoxantrone—Abdominal pain—Carmustine—lymphatic system cancer	6.37e-05	0.000995	CcSEcCtD
Mitoxantrone—Body temperature increased—Carmustine—lymphatic system cancer	6.37e-05	0.000995	CcSEcCtD
Mitoxantrone—Gastrointestinal pain—Vincristine—lymphatic system cancer	6.29e-05	0.000982	CcSEcCtD
Mitoxantrone—Pancytopenia—Methotrexate—lymphatic system cancer	6.23e-05	0.000974	CcSEcCtD
Mitoxantrone—Neutropenia—Methotrexate—lymphatic system cancer	6.13e-05	0.000959	CcSEcCtD
Mitoxantrone—Upper respiratory tract infection—Methotrexate—lymphatic system cancer	6.1e-05	0.000953	CcSEcCtD
Mitoxantrone—TOP2A—Azacitidine—Cytarabine—lymphatic system cancer	6.08e-05	0.0356	CbGdCrCtD
Mitoxantrone—Body temperature increased—Vincristine—lymphatic system cancer	6.08e-05	0.00095	CcSEcCtD
Mitoxantrone—Abdominal pain—Vincristine—lymphatic system cancer	6.08e-05	0.00095	CcSEcCtD
Mitoxantrone—Erectile dysfunction—Methotrexate—lymphatic system cancer	6.04e-05	0.000944	CcSEcCtD
Mitoxantrone—Hypersensitivity—Carmustine—lymphatic system cancer	5.93e-05	0.000927	CcSEcCtD
Mitoxantrone—Pneumonia—Methotrexate—lymphatic system cancer	5.88e-05	0.000919	CcSEcCtD
Mitoxantrone—Vomiting—Bleomycin—lymphatic system cancer	5.87e-05	0.000917	CcSEcCtD
Mitoxantrone—Drowsiness—Methotrexate—lymphatic system cancer	5.85e-05	0.000914	CcSEcCtD
Mitoxantrone—Rash—Bleomycin—lymphatic system cancer	5.82e-05	0.000909	CcSEcCtD
Mitoxantrone—Dermatitis—Bleomycin—lymphatic system cancer	5.81e-05	0.000908	CcSEcCtD
Mitoxantrone—Asthenia—Carmustine—lymphatic system cancer	5.78e-05	0.000903	CcSEcCtD
Mitoxantrone—Renal failure—Methotrexate—lymphatic system cancer	5.75e-05	0.000899	CcSEcCtD
Mitoxantrone—Stomatitis—Methotrexate—lymphatic system cancer	5.7e-05	0.000891	CcSEcCtD
Mitoxantrone—Conjunctivitis—Methotrexate—lymphatic system cancer	5.69e-05	0.000888	CcSEcCtD
Mitoxantrone—Hypersensitivity—Vincristine—lymphatic system cancer	5.66e-05	0.000885	CcSEcCtD
Mitoxantrone—Sweating—Methotrexate—lymphatic system cancer	5.61e-05	0.000876	CcSEcCtD
Mitoxantrone—Haematuria—Methotrexate—lymphatic system cancer	5.58e-05	0.000872	CcSEcCtD
Mitoxantrone—Asthenia—Vincristine—lymphatic system cancer	5.52e-05	0.000862	CcSEcCtD
Mitoxantrone—Diarrhoea—Carmustine—lymphatic system cancer	5.51e-05	0.000861	CcSEcCtD
Mitoxantrone—Nausea—Bleomycin—lymphatic system cancer	5.48e-05	0.000856	CcSEcCtD
Mitoxantrone—Agranulocytosis—Methotrexate—lymphatic system cancer	5.46e-05	0.000853	CcSEcCtD
Mitoxantrone—Haemoglobin—Methotrexate—lymphatic system cancer	5.28e-05	0.000825	CcSEcCtD
Mitoxantrone—Diarrhoea—Vincristine—lymphatic system cancer	5.26e-05	0.000822	CcSEcCtD
Mitoxantrone—Haemorrhage—Methotrexate—lymphatic system cancer	5.25e-05	0.000821	CcSEcCtD
Mitoxantrone—Hepatitis—Methotrexate—lymphatic system cancer	5.25e-05	0.000821	CcSEcCtD
Mitoxantrone—Pharyngitis—Methotrexate—lymphatic system cancer	5.21e-05	0.000814	CcSEcCtD
Mitoxantrone—Vomiting—Carmustine—lymphatic system cancer	5.12e-05	0.0008	CcSEcCtD
Mitoxantrone—Rash—Carmustine—lymphatic system cancer	5.08e-05	0.000794	CcSEcCtD
Mitoxantrone—Dermatitis—Carmustine—lymphatic system cancer	5.07e-05	0.000793	CcSEcCtD
Mitoxantrone—Headache—Carmustine—lymphatic system cancer	5.05e-05	0.000788	CcSEcCtD
Mitoxantrone—Vomiting—Vincristine—lymphatic system cancer	4.89e-05	0.000764	CcSEcCtD
Mitoxantrone—Rash—Vincristine—lymphatic system cancer	4.85e-05	0.000758	CcSEcCtD
Mitoxantrone—Dermatitis—Vincristine—lymphatic system cancer	4.84e-05	0.000757	CcSEcCtD
Mitoxantrone—Headache—Vincristine—lymphatic system cancer	4.82e-05	0.000753	CcSEcCtD
Mitoxantrone—Nausea—Carmustine—lymphatic system cancer	4.78e-05	0.000748	CcSEcCtD
Mitoxantrone—Chills—Methotrexate—lymphatic system cancer	4.71e-05	0.000736	CcSEcCtD
Mitoxantrone—Alopecia—Methotrexate—lymphatic system cancer	4.64e-05	0.000725	CcSEcCtD
Mitoxantrone—Erythema—Methotrexate—lymphatic system cancer	4.57e-05	0.000714	CcSEcCtD
Mitoxantrone—Nausea—Vincristine—lymphatic system cancer	4.57e-05	0.000714	CcSEcCtD
Mitoxantrone—Dysgeusia—Methotrexate—lymphatic system cancer	4.48e-05	0.000699	CcSEcCtD
Mitoxantrone—Back pain—Methotrexate—lymphatic system cancer	4.42e-05	0.000691	CcSEcCtD
Mitoxantrone—Vision blurred—Methotrexate—lymphatic system cancer	4.31e-05	0.000673	CcSEcCtD
Mitoxantrone—Ill-defined disorder—Methotrexate—lymphatic system cancer	4.24e-05	0.000663	CcSEcCtD
Mitoxantrone—Anaemia—Methotrexate—lymphatic system cancer	4.22e-05	0.00066	CcSEcCtD
Mitoxantrone—Malaise—Methotrexate—lymphatic system cancer	4.12e-05	0.000644	CcSEcCtD
Mitoxantrone—Leukopenia—Methotrexate—lymphatic system cancer	4.09e-05	0.000639	CcSEcCtD
Mitoxantrone—Cough—Methotrexate—lymphatic system cancer	3.99e-05	0.000623	CcSEcCtD
Mitoxantrone—Convulsion—Methotrexate—lymphatic system cancer	3.96e-05	0.000619	CcSEcCtD
Mitoxantrone—Arthralgia—Methotrexate—lymphatic system cancer	3.89e-05	0.000608	CcSEcCtD
Mitoxantrone—Chest pain—Methotrexate—lymphatic system cancer	3.89e-05	0.000608	CcSEcCtD
Mitoxantrone—Myalgia—Methotrexate—lymphatic system cancer	3.89e-05	0.000608	CcSEcCtD
Mitoxantrone—Discomfort—Methotrexate—lymphatic system cancer	3.84e-05	0.000601	CcSEcCtD
Mitoxantrone—Confusional state—Methotrexate—lymphatic system cancer	3.76e-05	0.000588	CcSEcCtD
Mitoxantrone—Anaphylactic shock—Methotrexate—lymphatic system cancer	3.73e-05	0.000583	CcSEcCtD
Mitoxantrone—Infection—Methotrexate—lymphatic system cancer	3.71e-05	0.000579	CcSEcCtD
Mitoxantrone—Thrombocytopenia—Methotrexate—lymphatic system cancer	3.65e-05	0.000571	CcSEcCtD
Mitoxantrone—Skin disorder—Methotrexate—lymphatic system cancer	3.62e-05	0.000566	CcSEcCtD
Mitoxantrone—Hyperhidrosis—Methotrexate—lymphatic system cancer	3.61e-05	0.000564	CcSEcCtD
Mitoxantrone—Anorexia—Methotrexate—lymphatic system cancer	3.56e-05	0.000556	CcSEcCtD
Mitoxantrone—Hypotension—Methotrexate—lymphatic system cancer	3.49e-05	0.000545	CcSEcCtD
Mitoxantrone—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	3.4e-05	0.000531	CcSEcCtD
Mitoxantrone—Paraesthesia—Methotrexate—lymphatic system cancer	3.35e-05	0.000523	CcSEcCtD
Mitoxantrone—Dyspnoea—Methotrexate—lymphatic system cancer	3.33e-05	0.00052	CcSEcCtD
Mitoxantrone—Somnolence—Methotrexate—lymphatic system cancer	3.32e-05	0.000518	CcSEcCtD
Mitoxantrone—Dyspepsia—Methotrexate—lymphatic system cancer	3.28e-05	0.000513	CcSEcCtD
Mitoxantrone—Decreased appetite—Methotrexate—lymphatic system cancer	3.24e-05	0.000507	CcSEcCtD
Mitoxantrone—Fatigue—Methotrexate—lymphatic system cancer	3.22e-05	0.000503	CcSEcCtD
Mitoxantrone—Pain—Methotrexate—lymphatic system cancer	3.19e-05	0.000499	CcSEcCtD
Mitoxantrone—Feeling abnormal—Methotrexate—lymphatic system cancer	3.07e-05	0.00048	CcSEcCtD
Mitoxantrone—Gastrointestinal pain—Methotrexate—lymphatic system cancer	3.05e-05	0.000477	CcSEcCtD
Mitoxantrone—Urticaria—Methotrexate—lymphatic system cancer	2.96e-05	0.000463	CcSEcCtD
Mitoxantrone—Body temperature increased—Methotrexate—lymphatic system cancer	2.95e-05	0.000461	CcSEcCtD
Mitoxantrone—Abdominal pain—Methotrexate—lymphatic system cancer	2.95e-05	0.000461	CcSEcCtD
Mitoxantrone—Hypersensitivity—Methotrexate—lymphatic system cancer	2.75e-05	0.00043	CcSEcCtD
Mitoxantrone—Asthenia—Methotrexate—lymphatic system cancer	2.68e-05	0.000418	CcSEcCtD
Mitoxantrone—Diarrhoea—Methotrexate—lymphatic system cancer	2.55e-05	0.000399	CcSEcCtD
Mitoxantrone—Vomiting—Methotrexate—lymphatic system cancer	2.37e-05	0.000371	CcSEcCtD
Mitoxantrone—Rash—Methotrexate—lymphatic system cancer	2.35e-05	0.000368	CcSEcCtD
Mitoxantrone—Dermatitis—Methotrexate—lymphatic system cancer	2.35e-05	0.000367	CcSEcCtD
Mitoxantrone—Headache—Methotrexate—lymphatic system cancer	2.34e-05	0.000365	CcSEcCtD
Mitoxantrone—Nausea—Methotrexate—lymphatic system cancer	2.22e-05	0.000346	CcSEcCtD
